Fibrinolysis and diabetes

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Hematology

Background:

• Diabetes mellitus is associated with impaired fibrinolysis, a key process in blood clot dissolution.
• This impairment is linked to elevated levels of plasminogen activator inhibitor type-1 (PAI-1) in tissues and circulation.
• The underlying mechanisms involve insulin resistance syndrome, characterized by high free fatty acids, triglycerides, and insulin levels.

Purpose of the Study:

• To investigate the relationship between diabetes and fibrinolytic system dysfunction.
• To explore the contributing factors to impaired fibrinolysis in diabetic patients.
• To identify therapeutic strategies for normalizing fibrinolytic capacity in diabetes.

Main Methods:

• Analysis of fibrinolytic markers, including PAI-1 concentrations.
• Assessment of metabolic parameters such as free fatty acids, triglycerides, and insulin.
• Evaluation of the impact of insulin resistance on fibrinolysis.

Main Results:

• Diabetic patients exhibit augmented PAI-1 levels, leading to reduced fibrinolytic activity.
• Elevated free fatty acids, triglycerides, and insulin, associated with insulin resistance, contribute to this derangement.
• Impaired fibrinolysis in diabetes can worsen existing coronary artery disease.

Conclusions:

• Normalization of fibrinolysis is a critical and attainable therapeutic goal in diabetes management.
• Interventions targeting the renin-angiotensin system, dyslipidemia, and insulin sensitivity can improve fibrinolytic function.
• Improving fibrinolysis may mitigate cardiovascular complications in diabetic individuals.